In the Aphinity phase III trial, randomizing HER2+ BC patients to receive either pertuzumab or placebo in combination with standard adjuvant chemotherapy plus trastuzumab, TILs were associated with iDFS when considering the two arms pooled, thus corroborating the positive prognostic impact of TILs in patients receiving adjuvant chemotherapy plus anti-HER2 blockade [34]. This evidence concerns the gene ERBB2 and breast cancer.